{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Yttrium_Y_90_DOTA_Anti-CEA_Monoclonal_Antibody_M5A",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A radioimmunoconjugate consisting of a monoclonal antibody directed against the human carcinoembryonic antigen (CEA) conjugated with the radioisotope yttrium 90 (Y-90) via the chelator tetra-azacyclododecanetetra-acetic acid (DOTA) with potential antineoplastic activity. The antibody moiety of yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A binds to cells expressing the CEA antigen. Upon cellular internalization, this agent selectively delivers a cytotoxic dose of beta radiation. CEA, a tumor associated antigen, is overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers.",
    "fdaUniiCode": "I9O4Z8CE5L",
    "identifier": "C77853",
    "preferredName": "Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C129819",
      "C1511"
    ],
    "synonyms": [
      "Y90-DOTA-M5A",
      "YTTRIUM Y-90 DOTA ANTI-CEA MONOCLONAL ANTIBODY M5A",
      "Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A",
      "yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A"
    ]
  }
}